Ani pharmaceuticals announces launch of nebivolol tablets

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced the launch of nebivolol tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ani's nebivolol tablets is the generic version of the reference listed drug (“rld”) bystolic®. the current annual u.s. market for bystolic 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately $1.05 billion, according to iqvia/ims health, a leading healthcare data and analytics provider. "the launch of nebivolol
ANIP Ratings Summary
ANIP Quant Ranking